This is an exclusive development and clinical manufacturing partnership for up to 8 antibody therapeutics including ABLBio’s biologics pipelines and collaboration programs between ABL Bio and I-Mab Biopharma (I-Mab)
WuXi Biologics, a global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, and ABL Bio Corporation (ABL Bio), a privately-held South Korean biotechnology company developing antibody therapeutics for immuno-oncology and neurodegenerative diseases, have announced an exclusive development and clinical manufacturing partnership for up to 8 antibody therapeutics including ABLBio’s biologics pipelines and collaboration programs between ABL Bio and I-Mab Biopharma (I-Mab).
The agreement showcases the expansive biologics pipeline of ABL Bio and the world leading technical expertise and capabilities of WuXi Biologics in developing bispecific programs.
“The partnership with WuXi Biologics is an important strategy for growing our internal and external programs of next-generation of biologics such as bispecific antibody. WuXi Biologics has enabled several preclinical and clinical manufacturing programs for ABL Bio as well as collaboration with I-Mab,” said Dr. Sang Hoon Lee, Chief Executive Officer of ABL Bio. “I believe that the partnership with WuXi Biologics will bring a synergy effect for developing our bispecific antibody pipelines and help us step up to be a global top-tier biotechnology company for immuno-oncology and neurodegenerative disease treatment.”
“We are excited about this exclusive partnership, our first in South Korea. WuXi Biologics has been well recognized as a global leader in the development and manufacturing of difficult biologics such as bispecific antibodies. This agreement continues to exemplify our technical strength and unparalleled capacity in global biologics development and manufacturing,” said Dr. Chris Chen, Chief Executive Officer of WuXi Biologics.